Andrew Huberman· PhD
only 10% are offered any therapy and they're most likely four to1 to be offered an anti-depressant that is where it stands today
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
only 10% are offered any therapy and they're most likely four to1 to be offered an anti-depressant that is where it stands today
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
For symptomatic perimenopausal women under 60, hormone replacement therapy reduces all-cause mortality.
The breast-cancer risk attributed to HRT in the original WHI trial was overstated and the timing window matters most.